MUC5AC与CA19-9联合应用提高胰腺癌诊断效能:一项多中心研究
本研究通过多中心训练集与验证集评估MUC5AC单独及联合CA19-9对胰腺癌的诊断价值。组织学显示MUC5AC在PanIN1A即从头表达并贯穿进展至浸润性腺癌。可切除早期胰腺癌与不可切除晚期胰腺癌患者循环MUC5AC中位数均显著高于良性对照和慢性胰腺炎对照(P≤0.0001),独立验证集证实其诊断潜力,联合CA19-9可显著改善可切除病例与对照的鉴别准确性(P<0.001)。
要点
- MUC5AC在PanIN1A即从头表达并维持至浸润性腺癌。
- 早期胰腺癌循环MUC5AC中位数67.2 ng/ml,显著高于良性对照7.2 ng/ml和慢性胰腺炎8.4 ng/ml(P≤0.0001)。
- MUC5AC联合CA19-9可显著改善可切除胰腺癌与对照的鉴别准确性(P<0.001)。
核心结论
- MUC5AC无论单独使用还是与CA19-9联合,均为区分胰腺癌与慢性胰腺炎及良性对照的有价值诊断生物标志物。
研究设计与样本
- 多中心研究,采用训练集与验证集设计;训练集共346例,其中诊断集241例、预测集105例(术前术后及化疗样本共201份)。
- 独立验证集来自Mayo Clinic(n=94)和University of Pittsburgh Medical Center(n=321),使用预先设定的截断值进行验证。
- 组织表达通过免疫组化评估,循环MUC5AC采用自制夹心ELISA测定,CA19-9采用放射免疫分析测定。
主要发现
- 组织学分析显示MUC5AC在胰腺上皮内瘤变1A(PanIN1A)即从头表达,并贯穿进展至浸润性腺癌的所有阶段。
- 可切除早期胰腺癌(1/2期)循环MUC5AC中位数67.2 ng/ml(IQR 23.9-382.1),不可切除晚期胰腺癌(3/4期)389.7 ng/ml(IQR 87.7-948.6),均显著高于良性对照7.2 ng/ml(IQR 0.4-26.5)和慢性胰腺炎对照8.4 ng/ml(IQR 1.5-19.2),P值均≤0.0001。
- 诊断训练集(n=241)中,MUC5AC区分早期胰腺癌与健康对照的敏感度/特异度为83%/80%,与良性对照为67%/87%,与慢性胰腺炎为83%/77%。
- Mayo Clinic验证集中,MUC5AC区分早期胰腺癌与良性对照的敏感度/特异度为68%/73%,与慢性胰腺炎为68%/79%;UPMC验证集中分别为65%/83%和65%/72%。
- MUC5AC与CA19-9联合可显著改善可切除病例与对照的鉴别诊断准确性(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Pancreatic cancer (PC) is a lethal malignancy that lacks specific diagnostic markers. The present study explores the diagnostic potential of the most differentially overexpressed secretory mucin MUC5AC alone and in combination with CA19-9 using multi-center training and validation sets. METHODS: The expression of MUC5AC in benign pancreatic pathologies, PC precursor lesions, primary PC tissues and metastatic lesions was evaluated by immunohistochemistry. Circulating MUC5AC levels were measured using sandwich ELISA assay developed in-house, and CA19-9 was measured using radioimmunoassay. A combined training set (n=346) was used to evaluate the diagnostic (n=241) and predictive (n=105, total samples 201 from pre- and post-surgical and chemotherapy set) significance of MUC5AC. Results were further validated with a pre-defined cut-off value using independent sets from the Mayo Clinic (n=94) and the University of Pittsburgh Medical Center (n=321). RESULTS: Tissue expression analyses indicated the de novo expression of MUC5AC in pancreatic intraepithelial precursor lesions 1A (PanIN1A); the expression was maintained through all stages of progression to invasive adenocarcinoma. The median circulating MUC5AC levels in patients with resectable early-stage PC (EPC) (stage 1/2; 67.2 ng/ml, IQR: 23.9-382.1) and unresectable late-stage PC (LPC) (stage 3/4; 389.7 ng/ml, IQR: 87.7-948.6) were significantly higher compared with (P-value ≤0.0001) benign controls (BC) (7.2 ng/ml, IQR: 0.4-26.5) and (P-value ≤0.0001) chronic pancreatitis (CP) controls (8.4 ng/ml, IQR: 1.5-19.2). In the diagnostic training set (n=241), MUC5AC efficiently differentiated EPC from healthy controls (HC) (83%/80% sensitive (SN)/specific (SP)), BC (67%/87% SN/SP), and CP (83%/77% SN/SP). Independent validation sets from the Mayo Clinic and UPMC confirmed the diagnostic potential of MUC5AC to differentiate EPC from BC (68%/73%; 65%/83%) and CP (68%/79%; 65%/72%). Furthermore, MUC5AC and CA19-9 combination significantly improved (p-value < 0.001) the diagnostic accuracy for differentiating resectable cases from controls. CONCLUSIONS: MUC5AC is a valuable diagnostic biomarker, either alone or in combination with CA19-9, to differentiate PC from CP and benign controls.
引用
- Kaur S, Smith LM, Patel A, et al. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Am J Gastroenterol. 2016. PMID: 27845339. doi:10.1038/ajg.2016.482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。